Abstract:Lysine deacetylases (KDACs or HDACs) regulate lysine acetylation. Genetic inactivation results in much stronger deacetylation defects on known targets compared to inhibitor treatment. Inhibitors have predominantly off‐target effects in cells, even at low inhibitor doses. The majority of observed biological effects of treatment with KDAC inhibitors are due to off‐target effects rather than the intended KDAC inhibition. Lysine deacetylases (KDACs or HDACs) are metal‐dependent enzymes that regulate lysine acetylation, a post‐translational modification that is present on thousands of human proteins, essential for many cellular processes, and often misregulated in diseases. The selective inhibition of KDACs would allow for understanding of the biological roles of individual KDACs and therapeutic targeting of individual enzymes. Recent studies have suggested that purportedly specific KDAC inhibitors have significant off‐target binding, but the biological consequences of off‐target binding were not evaluated. We compared the effects of treatment with two of the reportedly most KDAC‐selective inhibitors, Tubastatin A and PCI‐34051, in HT1080 cells in which the endogenous KDAC6 or KDAC8 gene has been mutated to inactivate enzyme catalysis while retaining enzyme expression. Genetic inactivation results in much stronger deacetylation defects on known targets compared to inhibitor treatment. Gene expression analysis revealed that both inhibitors have extensive and extensively overlapping off‐target effects in cells, even at low inhibitor doses. Furthermore, Tubastatin A treatment led to increased histone acetylation, while inactivation of KDAC6 or KDAC8 did not. Genetic inactivation of KDAC6, but not KDAC8, impaired tumor formation in a xenograft model system, in contrast to previous reports with KDAC inhibitors suggesting the reverse. We conclude that the majority of observed biological effects of treatment with KDAC inhibitors are due to off‐target effects rather than the intended KDAC inhibition. Developing a truly specific KDAC6 inhibitor could be a promising therapeutic avenue, but it is imperative to develop new inhibitors that selectively mimic genetic inactivation of individual KDACs.

Lysine Acetyltransferases and Lysine Deacetylases As Targets for Cardiovascular Disease

Histone Deacetylases in Modulating Cardiac Disease and Their Clinical Translational and Therapeutic Implications

Acetylation in Cardiovascular Diseases: Molecular Mechanisms and Clinical Implications

Targeting histone deacetylases for heart diseases

Lysine Ubiquitination and Acetylation of Human Cardiac 20S Proteasomes.

Abstract 31: Regulation of Acetylation Restores Proteolytic Function in Diseased Myocardium

Targeting histone deacetylase in cardiac diseases

Regulation of Acetylation Restores Proteolytic Function of Diseased Myocardium in Mouse and Human

Role of histone deacetylases in vascular cell homeostasis and arteriosclerosis.

Lysine Acetyltransferase Inhibitors From Natural Sources

Abstract P286: Acetylation Affords Enhanced Proteolytic Function in Normal and Diseased Myocardium

Mechanism of histone deacetylases in cardiac hypertrophy and its therapeutic inhibitors

Lysine deacetylase inhibitors have low selectivity in cells and exhibit predominantly off‐target effects

The role of class IIa histone deacetylases in regulating endothelial function

Protein Lysine Four‐carbon Acylations in Health and Disease

Regulation of cardiovascular diseases by histone deacetylases and NADPH oxidases

Critical review of non‐histone human substrates of metal‐dependent lysine deacetylases

Histone deacetylases: Regulation of vascular homeostasis via endothelial cells and vascular smooth muscle cells and the role in vascular pathogenesis

Histone Deacetylases (hdacs) and Atherosclerosis: A Mechanistic and Pharmacological Review

Protein lysine four-carbon acylations in health and disease

Regulation of cell metabolism by lysine acetylation